Immix Biopharma (NASDAQ:IMMX) Coverage Initiated by Analysts at Citizens Jmp

Equities researchers at Citizens Jmp began coverage on shares of Immix Biopharma (NASDAQ:IMMX) in a research note issued on Monday,Benzinga reports. The brokerage set a “market outperform” rating and a $23.00 price target on the stock. Citizens Jmp’s price objective suggests a potential upside of 147.58% from the company’s previous close.

Other research analysts have also recently issued research reports about the stock. Wall Street Zen raised shares of Immix Biopharma from a “sell” rating to a “hold” rating in a report on Saturday. Mizuho initiated coverage on Immix Biopharma in a research report on Monday, February 9th. They issued an “outperform” rating and a $14.00 target price on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immix Biopharma in a research note on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Immix Biopharma has a consensus rating of “Hold” and a consensus price target of $15.00.

Immix Biopharma Stock Performance

NASDAQ IMMX opened at $9.29 on Monday. Immix Biopharma has a one year low of $1.34 and a one year high of $9.47. The company has a market capitalization of $492.00 million, a price-to-earnings ratio of -12.06 and a beta of 0.25. The company’s 50-day simple moving average is $6.38 and its two-hundred day simple moving average is $4.50.

Hedge Funds Weigh In On Immix Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC purchased a new position in Immix Biopharma in the 4th quarter worth approximately $20,471,000. Eventide Asset Management LLC purchased a new stake in shares of Immix Biopharma in the fourth quarter valued at approximately $13,331,000. Marshall Wace LLP increased its holdings in shares of Immix Biopharma by 3,495.4% in the fourth quarter. Marshall Wace LLP now owns 1,978,743 shares of the company’s stock valued at $10,349,000 after purchasing an additional 1,923,708 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of Immix Biopharma in the fourth quarter valued at approximately $8,681,000. Finally, Adage Capital Partners GP L.L.C. purchased a new position in Immix Biopharma during the fourth quarter worth approximately $7,845,000. 11.26% of the stock is owned by hedge funds and other institutional investors.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.